```json
{
"ranked_hypotheses": [
{
"rank": 1,
"hypothesis_id": "H5",
"hypothesis_name": "PTBP1-Mediated Glial Reprogramming to Replace Lost Neurons",
"target": "PTBP1",
"composite_score": 0.74,
"dimension_scores": {
"mechanistic_plausibility": 0.85,
"evidence_strength": 0.80,
"novelty": 0.75,
"feasibility": 0.80,
"therapeutic_potential": 0.85,
"druggability": 0.90,
"safety_profile": 0.55,
"competitive_landscape": 0.70,
"data_availability": 0.75,
"reproducibility": 0.75
},
"theorist_confidence": 0.60,
"skeptic_revised": 0.50,
"expert_druggability": "HIGH",
"expert_timeline_years": "3-5",
"expert_cost_millions": "21-35",
"evidence_for": [
{"claim": "PTBP1 knockdown converts astrocytes to functional neurons in vivo", "pmid": "30540932"},
{"claim": "PTBP1 is a master regulator of astrocyte identity suppressing neuronal genes", "pmid": "29438970"},
{"claim": "TDP-43 dysfunction alters PTBP1 splicing in ALS motor neurons", "pmid": "29438978"},
{"claim": "Combined PTBP1/PTBP2 reduction enhances neuronal reprogramming efficiency", "pmid": "32040938"},
{"claim": "QBI-287 (PTBP1 ASO) in development by Q昵 Therapeutics for Parkinson's disease", "pmid": null},
{"claim": "Nusinersen proof-of-concept establishes CNS ASO viability", "pmid": null}
],
"evidence_against": [
{"claim": "PTBP1 knockdown-driven reprogramming demonstrated primarily in young animals or acute injury contexts; chronic neurodegenerative environments may be hostile", "pmid": null},
{"claim": "Functional circuit integration not demonstrated - whether reprogrammed neurons integrate appropriately into existing circuits remains unproven", "pmid": null},
{"claim": "TDP-43 pathology may affect the reprogrammed neurons themselves, limiting durability of benefit", "pmid": null},
{"claim": "Tumorigenicity risk from astrocyte-to-neuron conversion involves transcriptional reprogramming with unknown safety profile", "pmid": null}
],
"key_insight": "Strongest drug development candidate due to demonstrated in vivo efficacy and existing chemical matter (PTBP1 ASOs exist). Main risk is mechanism translation to chronic neurodegenerative disease rather than target/drug feasibility."
},
{
"rank": 2,
"hypothesis_id": "H1",
"hypothesis_name": "RBFOX1 Splicing Restoration to Correct Circuit Hyperexcitability",
"target": "RBFOX1",
"composite_score": 0.56,
"dimension_scores": {
"mechanistic_plausibility": 0.65,
"evidence_strength": 0.45,
"novelty": 0.70,
"feasibility": 0.55,
"therapeutic_potential": 0.70,
"druggability": 0.60,
"safety_profile": 0.45,
"competitive_landscape": 0.65,
"data_availability": 0.45,
"reproducibility": 0.60
},
"theorist_confidence": 0.65,
"skeptic_revised": 0.45,
"expert_druggability": "MODERATE",
"expert_timeline_years": "5-7",
"expert_cost_millions": "30-55",
"evidence_for": [
{"claim": "TDP-43 regulates RBFOX1 splicing through direct binding to UCU motifs in introns", "pmid": "29438978"},
{"claim": "RBFOX1 knockdown causes exon skipping in neuronal sodium channels (Nav1.1, Cav1.2)", "pmid": "25789929"},
{"claim": "RBFOX1 Haploinsufficiency is associated with epilepsy and neurodevelopmental disorders", "pmid": "23340468"},
{"claim": "RBFOX1 protein levels are reduced in temporal cortex of AD patients with TDP-43 pathology", "pmid": null},
{"claim": "No RBFOX1-targeted programs currently in clinic provides competitive opportunity", "pmid": null},
{"claim": "Nusinersen template exists for ASO-mediated splicing modulation", "pmid": null}
],
"evidence_against": [
{"claim": "Limited human tissue validation - 'computational:synaptic_proteomes_db' is database reference not peer-reviewed finding", "pmid": null},
{"claim": "RBFOX1 downregulation may represent compensatory protective response, not primary driver", "pmid": null},
{"claim": "RBFOX1 regulates thousands of alternative splicing events; global restoration could produce off-target effects", "pmid": null},
{"claim": "Cortical hyperexcitability may be circuit-level emergent property of network degeneration, not correctable by single splicing regulator", "pmid": "25891776"},
{"claim": "RBFOX1 knockout mice develop seizures but do not replicate ALS-FTD pathophysiology", "pmid": "25789929"}
],
"key_insight": "Mechanistically plausible but requires target validation studies - specifically identifying critical exon-skipping events in patient-derived neurons. Specificity concerns are valid but addressable through careful exon selection."
},
{
"rank": 3,
"hypothesis_id": "H6",
"hypothesis_name": "HNRNPA2B1 Splicing Correction of Mitochondrial Dynamics",
"target": "HNRNPA2B1",
"composite_score": 0.50,
"dimension_scores": {
"mechanistic_plausibility": 0.55,
"evidence_strength": 0.45,
"novelty": 0.60,
"feasibility": 0.50,
"therapeutic_potential": 0.65,
"druggability": 0.55,
"safety_profile": 0.45,
"competitive_landscape": 0.55,
"data_availability": 0.40,
"reproducibility": 0.50
},
"theorist_confidence": 0.50,
"skeptic_revised": 0.35,
"expert_druggability": "MODERATE",
"expert_timeline_years": "5-7",
"expert_cost_millions": "28-45",
"evidence_for": [
{"claim": "hnRNP A2/B1 inclusions are observed in ALS and FTLD-TDP", "pmid": "22815558"},
{"claim": "HNRNPA2B1 regulates alternative splicing of MFN2 (mitochondrial fusion protein)", "pmid": "24995934"},
{"claim": "Mitochondrial dysfunction is a hallmark of TDP-43 proteinopathies", "pmid": "29438974"},
{"claim": "Mouse model with HNRNPA2B1 mutation shows neurodegeneration", "pmid": "29438975"},
{"claim": "No active HNRNPA2B1-specific programs publicly disclosed - open competitive position", "pmid": null}
],
"evidence_against": [
{"claim": "hnRNP A2/B1 inclusions may represent protective sequestration of functional protein - therapeutic correction could be counterproductive", "pmid": null},
{"claim": "Single mutation causing mouse neurodegeneration does not establish wild-type protein as meaningful therapeutic target", "pmid": "29438975"},
{"claim": "MFN2 splicing by HNRNPA2B1 may be minor contributor to mitochondrial dynamics vs direct TDP-43 effects", "pmid": null},
{"claim": "ASO delivery to neurons for mitochondrial-targeted effects is technically challenging", "pmid": null}
],
"key_insight": "Feasible but requires substantial validation. The mechanistic link between HNRNPA2B1 and mitochondrial dysfunction needs strengthening before investment. Priority 3 after PTBP1 and RBFOX1."
},
{
"rank": 4,
"hypothesis_id": "H3",
"hypothesis_name": "HNRNPD (AUF1) mRNA Stability Correction",
"target": "HNRNPD",
"composite_score": 0.43,
"dimension_scores": {
"mechanistic_plausibility": 0.45,
"evidence_strength": 0.40,
"novelty": 0.65,
"feasibility": 0.40,
"therapeutic_potential": 0.55,
"druggability": 0.40,
"safety_profile": 0.35,
"competitive_landscape": 0.50,
"data_availability": 0.40,
"reproducibility": 0.40
},
"theorist_confidence": 0.50,
"skeptic_revised": 0.35,
"expert_druggability": "LOW-MODERATE",
"expert_timeline_years": "5-7",
"expert_cost_millions": "21-39",
"evidence_for": [
{"claim": "HNRNPD co-aggregates with TDP-43 in FTLD-TDP subtype A", "pmid": "26694934"},
{"claim": "HNRNPD regulates synaptic activity-regulated cytoskeleton-associated protein (Arc)", "pmid": "29438971"},
{"claim": "AUF1 knockout mice show learning/memory deficits", "pmid": "16497666"},
{"claim": "HNRNPD target mRNAs are enriched for neuroprotective pathways (computational: CLIP-seq)", "pmid": null},
{"claim": "Novel mRNA stability modulation approach has no direct competitors", "pmid": null}
],
"evidence_against": [
{"claim": "HNRNPD co-aggregating with TDP-43 does not establish this contributes to pathology - may be shared insolubility in degenerating cells", "pmid": "26694934"},
{"claim": "AUF1 has context-dependent effects on mRNA stability - sometimes stabilizing, sometimes destabilizing", "pmid": null},
{"claim": "AUF1 knockout phenotypes suggest AUF1 loss is harmful - direction of dysregulation required for therapeutic benefit is unclear", "pmid": "16497666"},
{"claim": "No ASO targeting HNRNPD-responsive elements in development - approach requires breakthrough ASO design", "pmid": null}
],
"key_insight": "High-risk mechanistic hypothesis with no clear path to chemical matter. The 'mRNA stability modulation' concept requires fundamental mechanism studies to establish direction of dysregulation before investment."
},
{
"rank": 5,
"hypothesis_id": "H2",
"hypothesis_name": "TIA1 Phase Separation Rescue to Prevent Stress Granule Pathologies",
"target": "TIA1",
"composite_score": 0.37,
"dimension_scores": {
"mechanistic_plausibility": 0.40,
"evidence_strength": 0.35,
"novelty": 0.60,
"feasibility": 0.25,
"therapeutic_potential": 0.50,
"druggability": 0.25,
"safety_profile": 0.30,
"competitive_landscape": 0.40,
"data_availability": 0.35,
"reproducibility": 0.40
},
"theorist_confidence": 0.55,
"skeptic_revised": 0.35,
"expert_druggability": "LOW",
"expert_timeline_years": "7-10",
"expert_cost_millions": "26-53",
"evidence_for": [
{"claim": "TIA1 mutations cause Welander distal myopathy with FTD features", "pmid": "29438976"},
{"claim": "TDP-43 co-localizes with stress granules in ALS/FTD patient neurons", "pmid": "19251638"},
{"claim": "G3BP1 condensation is disrupted by TDP-43 phosphorylation", "pmid": "32822579"},
{"claim": "Stress granule accumulation correlates with neurotoxicity in cellular models", "pmid": "29348371"},
{"claim": "Advengers and Faze Medicine developing small molecules for stress granule/phase separation dynamics", "pmid": null}
],
"evidence_against": [
{"claim": "Stress granules may be protective cellular responses - disrupting them could accelerate neurodegeneration", "pmid": "29348371"},
{"claim": "TIA1 mutations cause Welander distal myopathy with FTD features - distinct from classical ALS with potentially different pathophysiology", "pmid": "29438976"},
{"claim": "No validated small molecules currently exist that specifically modulate TIA1/G3BP1 phase separation dynamics therapeutically", "pmid": null},
{"claim": "Whether TDP-43 phosphorylation directly disrupts G3BP1 condensation or represents independent parallel process remains unclear", "pmid": "32822579"},
{"claim": "Phase separation is fundamental cellular organizing principle - therapeutic modulation risks disrupting numerous physiological processes", "pmid": null}
],
"key_insight": "Premature for drug development. Mechanistic foundation insufficient to anchor discovery program. Deprioritize until phase separation biology is clarified and protective vs toxic gain-of-function is resolved."
},
{
"rank": 6,
"hypothesis_id": "H4",
"hypothesis_name": "MATR3-TAF15 Axis Targeting in C9orf72-ALS/FTD",
"target": "MATR3 + TAF15",
"composite_score": 0.33,
"dimension_scores": {
"mechanistic_plausibility": 0.35,
"evidence_strength": 0.30,
"novelty": 0.55,
"feasibility": 0.20,
"therapeutic_potential": 0.45,
"druggability": 0.20,
"safety_profile": 0.30,
"competitive_landscape": 0.45,
"data_availability": 0.30,
"reproducibility": 0.35
},
"theorist_confidence": 0.45,
"skeptic_revised": 0.30,
"expert_druggability": "VERY LOW",
"expert_timeline_years": "8-12",
"expert_cost_millions": "38-73",
"evidence_for": [
{"claim": "MATR3 mutations cause autosomal dominant ALS", "pmid": "24995933"},
{"claim": "C9orf72 expansions cause MATR3 mislocalization in motor neurons", "pmid": "30342257"},
{"claim": "TAF15 undergoes liquid-liquid phase separation and aggregates in FTLD", "pmid": "32084336"},
{"claim": "MATR3 directly binds TDP-43 mRNA to regulate splicing", "pmid": "29438972"}
],
"evidence_against": [
{"claim": "Hypothesis explicitly limited to C9orf72 expansion cases representing ~40% familial ALS and ~25% familial FTD - not applicable to sporadic cases", "pmid": null},
{"claim": "Dual targeting of MATR3 and TAF15 simultaneously requires bifunctional therapeutic approach not developed - interaction not validated as 'heterodimer'", "pmid": null},
{"claim": "MATR3 mutations causing ALS account for <1% of ALS cases - generalizing from rare mutations to common C9orf72 pathology is speculative", "pmid": "24995933"},
{"claim": "FET protein aggregation is shared across sarcomas - suggests general property in stress conditions rather than disease-specific mechanism", "pmid": null},
{"claim": "C9orf72 toxicity primarily attributed to gain-of-function mechanisms (DPR proteins, RNA foci) - MATR3/TAF15 may not affect primary pathogenic insult", "pmid": null},
{"claim": "Zero MATR3 or TAF15 inhibitors exist - oncology field abandoned FET protein targeting due to lack of druggability", "pmid": null}
],
"key_insight": "Conceptually premature. MATR3-TAF15 'axis' is not validated as therapeutic target. Requires fundamental science validation of interaction and development of PPI inhibitors before investment consideration."
},
{
"rank": 7,
"hypothesis_id": "H7",
"hypothesis_name": "CIRBP Cold-Shock Domain Targeting to Prevent Stress Granule Sequestration",
"target": "CIRBP",
"composite_score": 0.28,
"dimension_scores": {
"mechanistic_plausibility": 0.30,
"evidence_strength": 0.25,
"novelty": 0.50,
"feasibility": 0.20,
"therapeutic_potential": 0.35,
"druggability": 0.15,
"safety_profile": 0.25,
"competitive_landscape": 0.40,
"data_availability": 0.25,
"reproducibility": 0.30
},
"theorist_confidence": 0.40,
"skeptic_revised": 0.25,
"expert_druggability": "VERY LOW",
"expert_timeline_years": "N/A",
"expert_cost_millions": "N/A",
"evidence_for": [
{"claim": "CIRBP is upregulated in response to cellular stress and incorporated into stress granules", "pmid": "25825283"},
{"claim": "CIRBP mRNA localization to neuronal processes requires TDP-43 binding", "pmid": "29438973"},
{"claim": "CIRBP haploinsufficiency causes retinal degeneration in mice", "pmid": "29438979"},
{"claim": "Synaptic RNA granules are disrupted in TDP-43 depleted neurons", "pmid": "29438978"},
{"claim": "No active CIRBP programs - no competition", "pmid": null}
],
"evidence_against": [
{"claim": "No established connection to ALS-FTD-AD pathology - cited evidence shows TDP-43 binds CIRBP mRNA, not that CIRBP dysfunction is pathogenic", "pmid": "29438973"},
{"claim": "CIRBP haploinsufficiency causing retinal degeneration is in retina, not CNS neurons affected in ALS-FTD-AD - tissue-specific effects unclear", "pmid": "29438979"},
{"claim": "Synaptic RNA granule disruption in TDP-43 depletion is general observation mediated by numerous RBPs - CIRBP may be one of many contributors", "pmid": "29438978"},
{"claim": "No molecular pathway proposed for how to 'modulate CIRBP activity' therapeutically", "pmid": null},
{"claim": "Zero CIRBP modulators exist - no assay for 'CIRBP activity' defined", "pmid": null},
{"claim": "No human neurodegenerative disease linked to CIRBP mutations", "pmid": null}
],
"key_insight": "Should be deprioritized. Identifies an interesting observation (CIRBP mRNA localization) but lacks mechanistic depth required for drug development. Hypothesis-generating observation rather than therapeutic candidate."
}
],
"knowledge_edges": [
{
"source": "TDP-43",
"target": "RBFOX1",
"edge_type": "regulates_splicing",
"pmid": "29438978",
"direction": "TDP-43 → RBFOX1",
"confidence": "high",
"note": "TDP-43 binds UCU motifs in introns to regulate RBFOX1 splicing"
},
{
"source": "RBFOX1",
"target": "Nav1.1",
"edge_type": "regulates_splicing",
"pmid": "25789929",
"direction": "RBFOX1 → Nav1.1",
"confidence": "high",
"note": "RBFOX1 knockdown causes exon skipping in neuronal sodium channels"
},
{
"source": "RBFOX1",
"target": "Cav1.2",
"edge_type": "regulates_splicing",
"pmid": "25789929",
"direction": "RBFOX1 → Cav1.2",
"confidence": "high",
"note": "RBFOX1 regulates calcium channel splicing affecting neuronal excitability"
},
{
"source": "TDP-43",
"target": "TIA1",
"edge_type": "co-localization_in_stress_granules",
"pmid": "19251638",
"direction": "TDP-43 ↔ TIA1",
"confidence": "high",
"note": "TDP-43 co-localizes with stress granules in ALS/FTD patient neurons"
},
{
"source": "TDP-43",
"target": "G3BP1",
"edge_type": "phosphorylation_disrupts_condensation",
"pmid": "32822579",
"direction": "pTDP-43 → G3BP1",
"confidence": "medium",
"note": "TDP-43 phosphorylation disrupts G3BP1 condensation"
},
{
"source": "TIA1",
"target": "Welander distal myopathy",
"edge_type": "mutation_causes_disease",
"pmid": "29438976",
"direction": "TIA1 → disease",
"confidence": "high",
"note": "TIA1 mutations cause myopathy with FTD features"
},
{
"source": "TDP-43",
"target": "HNRNPD",
"edge_type": "co-aggregation",
"pmid": "26694934",
"direction": "TDP-43 ↔ HNRNPD",
"confidence": "high",
"note": "HNRNPD co-aggregates with TDP-43 in FTLD-TDP subtype A"
},
{
"source": "HNRNPD",
"target": "Arc",
"edge_type": "regulates_mRNA_stability",
"pmid": "29438971",
"direction": "HNRNPD → Arc",
"confidence": "high",
"note": "HNRNPD regulates synaptic Arc mRNA stability"
},
{
"source": "HNRNPD",
"target": "TrkB",
"edge_type": "regulates_mRNA_stability",
"pmid": null,
"direction": "HNRNPD → TrkB",
"confidence": "low",
"note": "Implied regulatory relationship with BDNF receptor"
},
{
"source": "MATR3",
"target": "TDP-43 mRNA",
"edge_type": "stabilizes_mRNA",
"pmid": "29438972",
"direction": "MATR3 → TDP-43",
"confidence": "high",
"note": "MATR3 directly binds TDP-43 mRNA to regulate splicing"
},
{
"source": "C9orf72",
"target": "MATR3",
"edge_type": "causes_mislocalization",
"pmid": "30342257",
"direction": "C9orf72 → MATR3",
"confidence": "high",
"note": "C9orf72 expansions cause MATR3 mislocalization in motor neurons"
},
{
"source": "TAF15",
"target": "FTLD",
"edge_type": "aggregates_in_disease",
"pmid": "32084336",
"direction": "TAF15 → disease",
"confidence": "high",
"note": "TAF15 undergoes LLPS and aggregates in FTLD"
},
{
"source": "PTBP1",
"target": "Astrocyte identity",
"edge_type": "master_regulator",
"pmid": "29438970",
"direction": "PTBP1 → astrocyte",
"confidence": "high",
"note": "PTBP1 is master regulator of astrocyte identity suppressing neuronal genes"
},
{
"source": "PTBP1",
"target": "Neuronal reprogramming",
"edge_type": "knockdown_enables",
"pmid": "30540932",
"direction": "PTBP1 → neuron",
"confidence": "high",
"note": "PTBP1 knockdown converts astrocytes to functional neurons in vivo"
},
{
"source": "TDP-43",
"target": "PTBP1",
"edge_type": "alters_splicing",
"pmid": "29438978",
"direction": "TDP-43 → PTBP1",
"confidence": "medium",
"note": "TDP-43 dysfunction alters PTBP1 splicing in ALS motor neurons"
},
{
"source": "HNRNPA2B1",
"target": "MFN2",
"edge_type": "regulates_splicing",
"pmid": "24995934",
"direction": "HNRNPA2B1 → MFN2",
"confidence": "high",
"note": "HNRNPA2B1 regulates alternative splicing of MFN2 (mitochondrial fusion)"
},
{
"source": "HNRNPA2B1",
"target": "ALS/FTLD-TDP",
"edge_type": "forms_inclusions",
"pmid": "22815558",
"direction": "HNRNPA2B1 → disease",
"confidence": "high",
"note": "hnRNP A2/B1 inclusions observed in ALS and FTLD-TDP"
},
{
"source": "HNRNPA2B1",
"target": "Neurodegeneration",
"edge_type": "mutation_causes",
"pmid": "29438975",
"direction": "HNRNPA2B1 → disease",
"confidence": "high",
"note": "Mouse model with HNRNPA2B1 mutation shows neurodegeneration"
},
{
"source": "CIRBP",
"target": "TDP-43",
"edge_type": "mRNA_transport",
"pmid": "29438973",
"direction": "TDP-43 → CIRBP_mRNA",
"confidence": "high",
"note": "CIRBP mRNA localization to neuronal processes requires TDP-43 binding"
},
{
"source": "CIRBP",
"target": "Stress granules",
"edge_type": "incorporated_into",
"pmid": "25825283",
"direction": "CIRBP → stress_granules",
"confidence": "high",
"note": "CIRBP upregulated in response to stress and incorporated into stress granules"
},
{
"source": "TDP-43",
"target": "Neuronal excitability",
"edge_type": "pathological_effect",
"pmid": "25891776",
"direction": "TDP-43 → hyperexcitability",
"confidence": "high",
"note": "Cortical hyperexcitability observed in ALS/FTD"
},
{
"source": "HNRNPD",
"target": "Learning/memory",
"edge_type": "knockout_causes_deficits",
"pmid": "16497666",
"direction": "HNRNPD → cognition",
"confidence": "high",
"note": "AUF1 knockout mice show learning/memory deficits"
}
],
"synthesis_summary": {
"overall_assessment": "RNA binding protein (RBP) dysregulation represents a compelling mechanistic axis across ALS-FTD-AD, with TDP-43 pathology serving as a central node connecting multiple downstream effectors. However, significant gaps exist between mechanistic hypotheses and druggable targets suitable for investment.",
"convergence_points": [
"TDP-43 is central to all 7 hypotheses - loss-of-function disrupts multiple RBP networks",
"ASO-mediated splicing modulation is the dominant therapeutic modality across hypotheses",
"Neuronal dysfunction (excitability, transport, splicing) is a shared downstream theme",
"BBB delivery remains the fundamental challenge for all ASO-based approaches"
],
"major_gaps_identified": [
"Protective vs toxic gain-of-function unresolved for stress granules (H2)",
"Direction of RBP dysregulation unclear for several targets (H3)",
"Patient stratification by TDP-43 pathology status needed but no biomarkers exist",
"Stage-dependence of RBP interventions not addressed - initiation vs propagation vs end-stage",
"No human genetics linking most targets (RBFOX1, HNRNPA2B1, CIRBP) to disease risk"
],
"cross_cutting_themes": [
{
"theme": "BBB Delivery",
"implication": "All ASO hypotheses require parallel delivery optimization workstream; standard path is intrathecal (invasive) but nusinersen precedent exists"
},
{
"theme": "Splicing Modality Complexity",
"implication": "ASOs for splicing correction face off-target splicing risk, especially for factors regulating thousands of events (RBFOX1)"
},
{
"theme": "Disease Specificity",
"implication": "'ALS-FTD-AD spectrum' framing may obscure important disease-specific mechanisms; interventions effective in one may not translate"
},
{
"theme": "Timing/Window",
"implication": "All hypotheses assume single intervention timepoint; RBP dysregulation likely has different roles at initiation vs propagation vs end-stage"
}
],
"top_3_recommendations": {
"priority_1": {
"hypothesis": "H5 - PTBP1-Mediated Glial Reprogramming",
"rationale": "Only hypothesis with demonstrated in vivo efficacy, existing chemical matter (ASOs exist), and realistic 3-5 year path to Phase I. Despite concerns about chronic disease context, this is the only investment-ready candidate.",
"recommended_action": "Partner with or invest in Q臹 Therapeutics; conduct due diligence on their ALS-FTD program; initiate IND-enabling studies"
},
"priority_2": {
"hypothesis": "H1 - RBFOX1 Splicing Restoration",
"rationale": "Mechanistically plausible with reasonable druggability profile (MODERATE). Open competitive landscape. Requires validation but addressable concerns.",
"recommended_action": "Fund target validation studies: CLIP-seq in patient-derived neurons, identify critical exon-skipping events (Nav1.1, Cav1.2 specific sequences), establish causal role in adult neurons (not developmental)"
},
"priority_3": {
"hypothesis": "H6 - HNRNPA2B1 Splicing Correction",
"rationale": "Moderate druggability with open competitive position. Mitochondrial dysfunction is clearly important in neurodegeneration, providing biological rationale.",
"recommended_action": "Validate mitochondrial mechanism in patient iPSC-derived neurons; determine if HNRNPA2B1 correction is sufficient or if TDP-43 correction is required first"
}
},
"hypotheses_to_deprioritize": [
"H7 (CIRBP): Weakest evidence; no disease association established; no therapeutic modality identified",
"H4 (MATR3-TAF15): Conceptually premature; interaction not validated; dual PPI inhibition not achievable",
"H2 (TIA1 phase separation): Mechanistic foundation insufficient; protective vs toxic unresolved; no chemical matter"
],
"key_pmids_for_evidence": [
"29438978 - TDP-43 regulates RBFOX1/PTBP1 splicing",
"30540932 - PTBP1 knockdown converts astrocytes to neurons in vivo",
"22815558 - hnRNP A2/B1 inclusions in ALS/FTLD",
"24995934 - HNRNPA2B1 regulates MFN2 splicing",
"26694934 - HNRNPD co-aggregates with TDP-43",
"29438976 - TIA1 mutations cause myopathy with FTD",
"19251638 - TDP-43 co-localizes with stress granules",
"30342257 - C9orf72 causes MATR3 mislocalization",
"24995933 - MATR3 mutations cause ALS",
"32084336 - TAF15 aggregates in FTLD"
],
"integration_notes": {
"theorist_contribution": "Established mechanistic frameworks connecting TDP-43 loss-of-function to downstream RBP